Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

A. The following manufacturer/sponsor provided a submission for this appraisal:

  • Eli Lilly & Company Ltd

B. The evidence review group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre:J Jones, A Takeda, SC Tan, K Cooper, E Loveman, A Clegg, N Murray (July 2006). Gemcitabine for metastatic breast cancer.

C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They gave their expert personal views on gemcitabine plus paclitaxel by providing written and/or oral evidence to the Committee. They were also invited to comment on the Appraisal Consultation Document (ACD).

  • Professor Steve Heys, Professor of Surgical Oncology, nominated by the British Association of Surgical Oncologists as a clinical specialist

  • Dr Andreas Makris, Consultant Clinical Oncologist, nominated by the Royal College of Physicians as a clinical specialist

  • Dr Mark Verrill, Consultant Medical Oncologist, nominated by the Royal College of Physicians as a clinical specialist

  • Maria Leadbeater, Nurse Specialist Secondary Breast Cancer, nominated by Breast Cancer Care as a patient expert

  • Anna Wood, Policy and Campaigns Manager, nominated by Breast Cancer Care as a patient expert.